10-QPeriod: Q2 FY2003

QUEST DIAGNOSTICS INC Quarterly Report for Q2 Ended Jun 30, 2003

Filed July 31, 2003For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported strong financial results for the quarter and six months ended June 30, 2003. Revenue growth was robust, driven by the significant acquisition of Unilab Corporation and continued strength in average revenue per requisition, which benefited from a shift towards higher-value and gene-based testing. The company demonstrated improved operational efficiencies through its Six Sigma and standardization initiatives, leading to a decrease in cost of services and selling, general, and administrative expenses as a percentage of net revenues. Notably, bad debt expense saw a marked improvement, even with the inclusion of Unilab's operations. Despite increased interest expenses due to financing the Unilab acquisition, net income saw substantial increases year-over-year, reflecting the company's ability to grow its top line while managing costs effectively.

Key Highlights

  • 1Net revenues increased by 14.1% for the three months and 14.7% for the six months ended June 30, 2003, compared to the prior year periods, largely driven by the acquisition of Unilab.
  • 2Net income rose significantly, with $120 million reported for the three months and $208 million for the six months ended June 30, 2003, up from $87 million and $154 million, respectively, in the prior year.
  • 3Acquisition of Unilab Corporation for $698 million (including cash and stock) was completed in February 2003, significantly expanding the company's California presence.
  • 4Cost of services as a percentage of net revenues decreased to 57.6% for the quarter and 58.4% for the six months, reflecting efficiency gains.
  • 5Selling, general, and administrative expenses as a percentage of net revenues decreased to 24.3% for the quarter and 24.9% for the six months, driven by improved collection experience and Six Sigma initiatives.
  • 6Bad debt expense improved, decreasing as a percentage of net revenues to 4.8% for the quarter and 4.9% for the six months, despite the inclusion of Unilab.
  • 7Goodwill increased substantially from $1.79 billion to $2.52 billion, reflecting the Unilab acquisition and prior acquisitions.

Frequently Asked Questions

The acquisition of Unilab Corporation, completed in February 2003, was a primary driver of Quest Diagnostics' revenue growth. It contributed significantly to the reported 14.1% increase in net revenues for the three months and 14.7% for the six months ended June 30, 2003. The acquisition also increased goodwill on the balance sheet substantially.

Quest Diagnostics demonstrated improved cost management, with cost of services and selling, general, and administrative expenses decreasing as a percentage of net revenues. This was attributed to efficiency gains from Six Sigma and standardization initiatives, as well as an improvement in bad debt expense, which fell to 4.8% of net revenues for the quarter.

The company highlighted continued strength in average revenue per requisition due to a shift towards higher-value testing and gene-based tests. They also anticipate realizing $25 million to $30 million in annual synergies from the Unilab integration by the end of 2005. The company also authorized a $300 million share repurchase program, indicating confidence in future cash flows.

The report mentions potential challenges related to the implementation of HIPAA transaction standards, which could lead to increased costs and temporary disruptions. It also notes ongoing legal proceedings related to billing practices, though management believes existing reserves are sufficient and does not anticipate a material adverse effect on the company's overall financial condition.